LOUISVILLE, Ky., April 10, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services ("BrightSpring" or "BrightSpring Health Services") (NASDAQ: BTSG) announced today that its company Onco360, a leading independent oncology pharmacy, was selected as a national pharmacy partner by Alexion Pharmaceuticals for a first-in-class, oral, Factor D inhibitor, Voydeya (Danicopan) to treat patients with a rare, life-threatening disease of the blood called paroxysmal nocturnal hemoglobinuria (PNH) who are experiencing extravascular hemolysis (EVH).
Voydeya is FDA-approved as add-on therapy to Ultomiris (Ravulizumab) or Soliris (Eculizumab) for patients living with PNH that experience continued anemia, or EVH. This innovative drug will complement current treatment regimens and help regulate the immune system, providing control and preventing the destruction of healthy blood cells.
"While PNH is only curable via bone marrow transplantation, this innovative drug from Alexion is a significant advancement in the treatment of PNH with EVH and will help improve the lives of those impacted by this disease," said BrightSpring's President and CEO, Jon Rousseau. "We are extremely proud of Onco360 for being selected as the preferred pharmacy for Voydeya as it shows the company's commitment to supporting cutting-edge treatment options the best possible way for patients living with cancer and complex diseases. We commend their leadership in partnering with biopharmaceutical leaders to continually innovate the proven standard-of-care."
"Onco360 is grateful and honored to partner with Alexion Pharmaceuticals to treat and support patients living with PNH with EVH and improve their quality of life," said Benito Fernandez, Chief Commercial Officer at Onco360. "This is another highly specialized, first-in-class drug that will complement current treatment regimens, and we're proud to be a trusted pharmacy and implement leading clinical and service practices for this drug and patients."
Onco360operates with the mission to improve the lives of patients battling cancer and living with other challenging and rare diseases. The pharmacy has robust access to limited distribution oncology medications and offers personalized services such as financial assistance sourcing, insurance benefit verification, expert clinical counseling, physician, patient and family education and support, rapid and accurate order processing and drug fulfillment, real-time digital and data support, Hub services, and 24/7 patient support.
肯塔基州路易斯維爾，2024年4月10日（GLOBE NEWSWIRE）——BrightSpring Health Services（“BrightSpring” 或 “BrightSpring Health Services”）（納斯達克股票代碼：BTSG）今天宣佈，旗下領先的獨立腫瘤藥房公司Onco360被Alexion Pharmaceuticals選爲全國藥房合作伙伴，爲一種首創的口服D因子抑制劑Voydeya (Danicopan)提供服務，用於治療一種罕見、危及生命的血液疾病--陣發性夜間血紅蛋白尿症（PNH）的血管外溶血（EVH）患者。
Voydeya已獲美國食品藥品管理局批准，可作爲Ultomiris（Ravulizumab）或Soliris（Eculizumab）的附加療法，適用於持續出現貧血（EVH）的PNH患者。這種創新藥物將補充當前的治療方案，幫助調節免疫系統，控制和防止破壞健康的血細胞。
BrightSpring總裁兼首席執行官喬恩·盧梭表示：“雖然PNH只能通過骨髓移植來治癒，但Alexion的這種創新藥物在使用EVH治療PNH方面取得了重大進展，將有助於改善受這種疾病影響的人的生活。”“我們爲Onco360被選爲Voydeya的首選藥房感到非常自豪，這表明該公司致力於以最佳方式爲癌症和複雜疾病患者提供尖端治療選擇。我們讚揚他們在與生物製藥領導者合作以不斷創新久經考驗的護理標準方面發揮的領導作用。”
Onco360首席商務官貝尼託·費爾南德斯表示：“Onco360很感激也很榮幸能與Alexion Pharmicals合作，爲患有EVH的PNH患者提供治療和支持，並改善他們的生活質量。”“這是另一種高度專業化的同類首創藥物，它將補充當前的治療方案，我們很自豪能夠成爲值得信賴的藥房，併爲這種藥物和患者實施領先的臨床和服務實踐。”
onco360的使命是改善與癌症作鬥爭以及患有其他具有挑戰性和罕見疾病的患者的生活。該藥房可以大量獲得限量分銷的腫瘤藥物，並提供個性化服務，例如經濟援助採購、保險福利驗證、專家臨床諮詢、醫生、患者和家庭教育與支持、快速準確的訂單處理和藥物履行、實時數字和數據支持、中心服務以及全天候患者支持。
